Kornimate/medical-research-clean huggingface dataset:
trial assessing the efficacy of a short course of intravenous antibiotic followed by oral antibiotic in uncomplicated acute diverticulitis

Conditions: Diverticulitis

Summary: medical treatment of uncomplicated acute diverticulitis is not standardized and there is an enormous diversity in clinical practice. the investigators' aim was to demonstrate that uncomplicated diverticulitis can be managed with oral amoxicillin plus clavulanic acid with a short hospital admission.

a prospective randomized trial was established to compare patients with uncomplicated diverticulitis who received oral antibiotic after a short course of intravenous antibiotic, with those who received intravenous antibiotic for a longer period. we included 50 patients, 25 in each group. patients in group 1 begun oral antibiotic as soon as they improved and were discharged the day after. patients in group 2 received intravenous antibiotic for 7 days. both groups received oral antibiotic at discharge. the endpoint of the study was "failure of treatment" which was defined as the impossibility of discharging on the expected day, emergency admission or hospital readmission.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of uncomplicated acute diverticulitis confirmed by a computed tomography (ct) scan within 24-48 hours exclusion criteria (prerandomization): * immunocompromised patients * pregnant women * clinical suspicion or ct confirmation of complicated acute diverticulitis * karnofsky performance score less than 50% * allergy to penicillin exclusion criteria (postrandomization): * withdrawal of the trial * ct confirmation of complicated acute diverticulitis * ct not conforming to acute diverticulitis * ct performed 72 hours after the admission * adverse reaction to the antibiotic * bacteriemia

Keywords: diverticulitis
combined locoregional treatment with immunotherapy for unresectable hcc.

Conditions: Hepatic Carcinoma

Summary: efficacy and safety of locoregional treatments combined with pd-1 inhibitor in patients with unresectable hepatocellular carcinoma.

hepatocellular carcinoma is the most frequent primary and ranked as the sixth most common neoplasm and the third leading cause of cancer death. percutaneous ablation and tace are the effective locoregional treatments for the patient with hcc. moreover, some studies suggested that tace combined with ablation could further improve the survival rate and reduce the post-operation complication. although pd-1 inhibitor was approved by fda for hcc, the latest rct indicated that no significant difference was found in the orr and pfs between the groups of pd-1 inhibitor and sorafenib. therefore, this study aims to assess the efficacy and safety of microwave ablation combined with simultaneous tace plus pd-1 inhibitor for the non-resectable hcc.

Eligibility criteria:
inclusion criteria: 1. age: 18 - 80 years old and life expectancy of at least 12 weeks.; 2. clinically or histologically diagnosed as hcc and the diameter of target tumor lesion ≥ 5 cm; 3. child-pugh classification a or b (score \< 7); 4. bclc staging as b or c; 5. ecog 0-1; 6. patients voluntarily entered the study and signed informed consent form (icf). exclusion criteria: 1. history of treatment with any local treatment (exception of liver transplantation), systemic .anti-cancer therapy, or immunotherapy; 2. the surgeon assessed that the tumor lesion was not unsuitable for microwave ablation; 3. any contraindications for hepatic embolization procedures: 1. known hepatofugal blood flow; 2. total thrombosis of main portal vein. 4. the tumor thrombus of main portal vein, ivc or right atrium; 5. tumor burden ≥ 70% of liver volume; and no measurable site of disease as defined by modified recist (mrecist) criteria with spiral ct scan or mri; 6. subjects with chronic hbv infection have hbv dna viral load \> 100 iu/ml at screening, and have not received antiviral therapy prior to initiation of study therapy; in addition, coinfection of hbv and hcv; 7. the alcoholic or pregnant women; 8. patients with second primary cancer or history of other cancer within 3 years; 9. diagnosis of active autoimmune disease, immunodeficiency, or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of sintilimab-monotherapy treatment; 10. blood count, liver function: haemoglobin \ 3 mg/dl; aspartate aminotransferase (sgot) or alanine aminotransferase (sgpt) \> 5 x upper normal limit (uln), albumin \ 2.3; 11. renal function dysfunction: serum creatinine \>2 mg/dl or creatinine clearance (crcl) \< 30 ml/min (if using the cockcroft-gault formula ); and severe heart, lung, brain or other organ disease; 12. non-compliance with tace or ablation procedure.

Keywords: hcc microwave ablation tace immunotherapy
a study on the effects on glucose regulation, inflammation and serum lipids after fish protein supplementation in elderly (gripe)

Conditions: Muscle Weakness; Muscle Loss; Blood Sugar; High; Inflammation; Aging

Summary: the elderly population have and increased risk of loss of both muscle mass and function and is therefore recommended a higher protein intake than the healthy adult population. these age-related changes in muscle function may be explained by chronic low-grade inflammation and insulin resistance. despite the recommendation of a higher protein intake, little is known about how different protein sources may affect the metabolic health in this population. analysis of amino acid composition show that fish can be a good protein source for humans. many fish species are today used as feed ingredients, rather than a protein source for humans. a few studies conducted in humans and rats show that proteins from fish may improve glucose tolerance, reduce inflammation and improve lipid metabolism, indicating that proteins from fish may not only serve as a valuable nutrient but could also hold specific health promoting properties. the present study will investigate the effects of a protein hydrolysate from blue whiting, a fish species normally used to produce fish meal for aquaculture industry, on glucose homeostasis, inflammation and serum lipids in elderly nursing home residents.

participants receive 6g per day of protein hydrolysate from blue whiting as protein powder mixed with a non-caloric juice for 6 weeks.

Eligibility criteria:
inclusion criteria: * \>60 years * both genders * nursing home resident exclusion criteria: * life expectancy \< 6 months * severe cognitive impairment * allergies towards fish, milk, egg * weight loss \>5% last 3 months
hydroxychloroquine as post exposure prophylaxis for sars-cov-2(hope trial)

Conditions: Contact Person From COVID-19 Confirmed Patient

Summary: there is no known definite treatment after exposure to sars-cov-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (hcq) or chloroquine against sars-cov-2. thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for sars-cov-2. * primary end point: comparison the rate of covid-19 between pep with hcq and control group. * secondary end point: comparison of the rate of covid-19 according to the contact level (time, place, degree of wearing personal protective equipment). * safety comparison: safety verification by identifying major side effects in the hcq group."


Eligibility criteria:
inclusion criteria: * a contact person from confirmed case of sars-cov-2 infection * medical staff exposed from confirmed case of sars-cov-2 infection in hospitals * persons exposed to sars-cov-2 in covid-19 outbreak situation with certain workplaces, religious groups, and military, etc. * subjects of study include both symptomatic and asymptomatic contacts. exclusion criteria: * hypersensitivity to chloroquine or hydroxychloroquine * those who are contraindicated in hydroxychloroquine administration according to the permission requirements such as pregnant women, nursing mothers, visual disorders, macular disease, and porphyria, etc. * human immunodeficiency virus (hiv) infected person * patients with autoimmune disease (systemic lupus erythematosus, mixed connective tissue disease) * patients with autoimmune rheumatoid inflammatory disease (aiird; autoimmune inflammatory rheumatic diseases - ankylosing spondylitis, rheumatic arthritis, psoriatic arthritis) * arrhythmia, liver cirrhosis of child pugh c, chronic renal failure with egfr≤30ml / min / 1.73m2 * a person who is positive in the covid-19 screening pcr test before starting pep

Keywords: postexposure prophylaxis hydroxychloroquine sars-cov-2 covid-19
spontaneous coronary artery dissection national swiss registry

Conditions: Spontaneous Coronary Artery Dissection

Summary: spontaneous coronary artery dissection (scad), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death. timely diagnosis of scad as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. despite recent improvements in diagnosis and recognition of the importance of scad, it remains poorly studied and understood. in this context, we designed the swissscad registry, a large, observational, prospective, cohort study, to describe the natural history of scad, its outcomes and its treatments.


Eligibility criteria:
inclusion criteria: * subject is ≥18 years of age. * patient presenting newly diagnosed scad or diagnosed with scad within the last 5 years. * subject must be willing to sign a patient informed consent (pic). exclusion criteria: * patient unwilling or unable to provide informed consent. * patients with atherosclerotic or iatrogenic coronary dissection.
safety and efficacy of propranolol 0.2% eye drops in treating retinopathy of premature: a pilot study (drop-rop-0.2%)

Conditions: Retinopathy of Prematurity

Summary: the aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (rop). preterm newborns (gestational age 23-32 weeks) with a stage 1 rop will receive propranolol 0.2% eye drops treatment until retinal vascularization will be completed, but no more than 90 days. propranolol concentrations will be measured on dried blood spots at the steady state (10th day). cardiovascular and respiratory parameters will be continuously monitored. blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the rop progression and the possible complications.


Eligibility criteria:
inclusion criteria: * preterm newborns (gestational age 23-32 weeks) with stage 1 rop * a signed parental informed consent exclusion criteria: * newborns with heart failure * newborns with recurrent bradycardia (heart rate \< 90 beat per minute) * newborns with second or third degree atrioventricular block * newborns with congenital cardiovascular anomalies, except for persistent ductus arteriosus, patent foramen ovale and small ventricular septal defects * newborns with hypotension * newborns with renal failure * newborns with actual cerebral haemorrhage * newborns with other diseases which contraindicate the use of beta-adrenoreceptor blockers. * newborns with a more severe stage of rop than stage 1

Keywords: retinopathy of prematurity propranolol newborn eye drops retinal angiogenesis retinal neovascularization
education for adapted physical activity in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease is a progressive disorders characterized by motor and non-motor symptoms. actual medical treatments are symptomatic and have little efficacy on late stage axial motor symptoms. non-pharmacological approaches are therefore essential from the disease onset. beside physiotherapy, to practice a regular adapted physical activity is crucial. to implement such a practice in everyday life implies to change habits. patient education programs are useful tools to help changing behaviors. the study evaluate the effect of a program aiming to promote adapted physical activity in early stage parkinson's disease by comparing patients receiving the program and patients on a waiting list. the hypothesis that the program will increase the one-week mean daily moderate to intense physical activity as measured with an actimeter.


Eligibility criteria:
inclusion criteria: * suffering from parkinson's disease according to movement disorders society criteria, * with a diagnosis of parkinson for 3 years or less, * with a stable treatment for parkinson's disease for 3 months or more, * having signed the consent form exclusion criteria: * woman child-bearing or breath-feeding * co-morbidities that influence or contraindicated adapted physical activity (severe respiratory symptoms, cardiopathy...) * major depressive disorder according to dsm-v * significant cognitive trouble (moca\<23) * atypical parkinson's

Keywords: therapeutic patient education adapted physical activity actimetry secondary prevention sensor monitoring
minimally invasive tricuspid surgery vs medical treatment for severe tr

Conditions: Tricuspid Regurgitation

Summary: late tricuspid regurgitation (tr) is a common complication after left-sided valve surgery (lsvs), which usually progresses slowly and results in right heart failure at terminal stage. over the past 3 decades, with the advances in minimally invasive surgical techniques, operative mortality after reoperation for severe tr has significantly decreased from 30% to 3-8%, leading to a gradual shift from medical therapy alone to surgery in those patients. however, there has been no consensus on the clinical benefit of minimally invasive tricuspid surgery over medical therapy for severe tr after lsvs.

in this multi-center randomized controlled trial, patients with severe tr after lsvs will be recruited. the patients will be randomly assigned to surgery plus medical therapy (surgery group) or medical therapy alone (control group). the primary outcome will be a composite of all-cause mortality, re-admission for right heart failure or the composite. furthermore, echocardiography-based measurement of right heart function, new york heart association functional class, liver and kidney function, and quality of life will be compared between the 2 groups. all outcomes will be assessed at baseline and 6, 12 and 24 months after randomization.

Eligibility criteria:
inclusion criteria: 1. severe tricuspid regurgitation, as assessed by the clinical site echocardiographer using the transthoracic echocardiography. 2. a history of lsvs, including one or multiple procedures of aortic and/or mitral valve repair and/or replacement. 3. left ventricular ejection fraction (lvef) \>45%, systolic pulmonary artery pressure \<60 mmhg with pulmonary vascular resistance \<6 woods unit. 4. age ≥ 18 years. 5. able to sign informed consent forms. exclusion criteria: 1. tr due to: infective endocarditis, congenital tricuspid valve malformation, secondary to correction of congenital heart disease. 2. left-sided valve dysfunction or coronary artery disease requiring concomitant procedures. 3. prior surgical or percutaneous tricuspid valve intervention. 4. evidence of an acute myocardial infarction in the prior 90 days 5. contraindications to cardiopulmonary bypass or the expected operative mortality \>30% (calculated by the society of thoracic surgeons score or the euroscore ii). 6. any comorbidity with life expectancy \<2 years 7. recent history of psychiatric disease (including drug or alcohol abuse) that is likely to impair compliance with the study protocol. 8. pregnancy at the time of randomization.
obstetrics , prenatal outcomes in recurrent miscarriage

Conditions: Recurrent Miscarriage

Summary: the effect of recurrent miscarriage on the outcome of the current pregnancy and if there's a relation between it and adverse out come


Eligibility criteria:
inclusion criteria: 1- patients who had ≥2 abortions during early pregnancy 2.patients had no abnormal reproductive tract anatomy 3. pregnant in single fetus exclusion criteria: chronic hypertension, chronic kidney diseases autoimmune diseases multiple pregnancy
assessment of proprioceptive and functional characteristics in patients with hemophilia

Conditions: Hemophilia

Summary: analyze and evaluate the skeletal muscle of patients affected with hemophilia in the region of murcia. * describe the periarticular muscular deficit of the lower limbs, depending on the degree of injury: acute and chronic, or subacute. * identify the range of motion of joints with higher prevalence of hemophilic arthropathy. * detect the biomechanical changes of the lower limbs and their impact on gait in patients with hemophilia. * assess the factors that influence the perception of illness and quality of life of patients with hemophilia.

descriptive study of joint involvement in hemophilia patients with and without a history of hemarthrosis in lower limbs. descriptive study of alterations in the strength of the periarticular muscles of lower limbs as a result of acute conditions or the development of chronic articular sequelae. descriptive study of the biomechanical alterations in weight-bearing joints of lower limbs and their impact on gait in patients with hemophilia. descriptive study of the relationship between skeletal muscle pathology in patients with hemophilia and their perceptions of it and their quality of life.

Eligibility criteria:
inclusion criteria: * patients with hemophilia a and b * patients of all ages (from 6 to 70 years). * with or without joint damage clinically diagnosed, and with or without a previous history of hemarthrosis joint load legs. * residents in the autonomous community of the region of murcia. exclusion criteria: * patients without ambulation * patients diagnosed with other congenital coagulopathy (von willebrand disease, etc..). * patients with neurological or cognitive impairments that prevent understanding the questionnaires and physical tests.

Keywords: hemophilia arthropathy range of motion strength proprioception gait quality of life
study to test the safety of increasing multiple doses of bay2328065 given by mouth, how the drug is tolerated and acts in the human body of healthy male participants. alteration of the study drug effects by another drug and the availability of the drug given in different formulations is also tested.

Conditions: Endometriosis

Summary: study on the safety and tolerability of a new drug bay2328065 when given increased doses as tablet or solution over 12 days to healthy male participants. researcher want to study how the body absorbs, breaks down and excrete the new drug, also when given together with a test meal. in addition the study will investigate changes that take place in the body when bay2328065 is given together with another drug.


Eligibility criteria:
inclusion criteria: * participant must be 18 to 50 years of age inclusive, at the time of signing the informed consent * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, ecg and vital signs * confirmation of the subject's health insurance coverage prior to the first screening examination/visit * body mass index (bmi) within the range 18 and 30 kg/m\^2 (inclusive) * male participants who are sexually active must agree to use two reliable and acceptable methods of contraception simultaneously (one method used by the study participant and one method used by the partner) and not to act as sperm donor until follow-up * capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol * the informed consent must be signed before any study specific tests or procedures are done * ability to understand and follow study-related instructions exclusion criteria: * incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention will not be normal * relevant diseases within the last 4 weeks prior to start of the first study intervention * known severe allergies, non-allergic drug reactions, or multiple drug allergies * existing chronic diseases requiring medication * history of cardiovascular disease * known diseases as specified in protocol * regular use of therapeutic or recreational drugs * suspicion of drug or alcohol abuse * smoking equal or more than 10 cigarettes/day * clinically relevant findings in electrocardiogram (ecg), blood pressure, heart rate, physical examination, laboratory examination * history of covid-19 * contact with sars-cov-2 positive persons or covid-19 patients within the last 4 weeks prior admission to the ward * positive sars-cov-2 viral rna test
investigating pathological mechanisms in non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: to identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease

in this study, the investigators will collect tissue, blood, stool, urine and saliva samples at the same time in order to enable a comprehensive disease phenotyping and ability to compare immunological, microbiological and metabolic features in patients with varying stages of nafld and healthy controls. to date there are limited published data evaluating simultaneously-obtained samples from adipose, gut and liver tissue and peripheral blood in nafld. the majority of participants in this study will be recruited from the bariatric surgery services enabling multiple tissue samples to be collected at time of surgery with minimal additional risk to participants.

Eligibility criteria:
inclusion criteria: * age ≥18 years * confirmed non-alcoholic fatty liver disease (diagnosed clinically, radiologically or histologically) * if diabetic, diagnosed with type 2 diabetes mellitus or • healthy control: no diagnosis of any liver condition including nafld o nafld excluded by fibroscan controlled attenuation parameter (cap) score of \<222 db/m exclusion criteria: * unwilling or unable to give informed consent * type 1 diabetes mellitus * other form of liver disease (other than nafld) o viral hepatitis, auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, sarcoidosis, cystic fibrosis, sickle cell disease * taking medication associated with liver dysfunction (except methotrexate) * auto-immune disease which in the investigator's opinion may confound immune profiling * concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids) * currently pregnant * any major organ transplant (excluding corneal or hair transplant) * regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants